NY-J.P.-MORGAN
6.6.2019 13:32:03 CEST | Business Wire | Press release
J.P. Morgan’s focus and investment in global e-commerce payments is paying off with top rankings from The Nilson Report, the independent payments industry source:
| #1 e-commerce provider in Europe (by web transaction volume)1 |
| #4 merchant acquirer in Europe (by overall transaction volume)2 |
According to The Nilson Report, J.P. Morgan processes almost 30% of all web transactions in Europe,3 ranging from multinationals headquartered in Europe and the U.S. to local European businesses with global ambitions. E-commerce in Europe is large and growing and is expected to exceed EURO 851.03 billion in spend by 2021,4 according to Edgar, Dunn & Company.
“E-commerce has created a seismic shift in the way consumers shop and pay for their purchases and this trend is evidenced by our growth from the sixth to the fourth largest merchant acquirer in Europe,” said Catherine Moore, President of Europe for J.P. Morgan Merchant Services. “As a pure-play e-commerce acquirer in Europe, we help merchants optimise their overall cost of payments and maximise business profitability.”
E-commerce merchants are not only benefitting from significant growth in Europe, but also dealing with complexities of compliance with the European Union’s Second Payment Services Directive (PSD2) and Strong Customer Authentication (SCA) coming into force this September.
“The key is finding the right balance between protecting the consumer and providing a seamless payments experience that helps merchants drive down fraud levels,” Moore said. “We are PSD2-ready and collaborating closely with all industry stakeholders to help make this game-changing directive a success both for the industry and consumers.”
J.P. Morgan was also recently named the #1 merchant acquirer in the U.S.5 (by purchase volume) by The Nilson Report and #1 merchant acquirer in the U.S.6 by The Strawhecker Group in 2019.
Learn more about J.P. Morgan’s global payments offerings, PSD2/SCA or request a consultation by visiting https://www.jpmorgan.com/europe/merchant-services .
About J.P. Morgan
J.P. Morgan offers a full suite of payments services to enable a seamless connection across the payments continuum for clients. We bring our consultative expertise, data-driven insights, and local service around the globe to provide a more unified view of payables, receivables and cash management. Merchant Services is the payment acceptance and merchant acquiring business of JPMorgan Chase & Co. (NYSE: JPM) – a global financial services firm with assets of $2.6 trillion and operations worldwide.7 According to The Nilson Report, it is also the top merchant acquirer of e-commerce transactions in Europe.8
| 1 The Nilson Report #1153, May 2019 | ||||||||
| 2 The Nilson Report #1153, May 2019 | ||||||||
| 3 The Nilson Report #1153, May 2019 | ||||||||
| 4 Global Payments Depository, Edgar, Dunn & Company, 2018 | ||||||||
| 5 The Nilson Report #1149, March 2019 | ||||||||
| 6 Directory of U.S. Merchant Acquirers (TSG Top 300), The Strawhecker Group, March 2019 | ||||||||
| 7 JPMorgan Chase & Co. Q4 2018 Earnings Report 2018 | ||||||||
| 8 The Nilson Report #1153, May 2019 | ||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005205/en/
Contact:
Media Contacts Allison Tobin Reed, Vice President, Communications, J.P. Morgan Email: allison.reed@jpmchase.com
Ludo Baynham-Herd, Associate Director, FleishmanHillard Fishburn Email: ludo.baynham-herd@fhflondon.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
